TWF1 inhibition overcomes cisplatin resistance in NSCLC by inducing ferroptosis via p53-dependent SLC7A11 repression and autophagy-mediated glutathione metabolism reprogramming
Sep 2026· Cancer Gene Therapy· Vol 33, pp. 1126 - 1140· 0 citations· 56 references
Medicine
TL;DR
TTF1 is identified as a critical regulator of cisplatin resistance and ferroptosis, highlighting the therapeutic potential of TWF1 inhibition combined with cisplatin to overcome chemoresistance, possibly providing new strategies for improving NSCLC treatment outcomes.
Chemoresistance remains a major barrier in non-small cell lung cancer (NSCLC) therapy. Glutathione reductase (GSR), a central regulator of glutathione redox homeostasis, has been implicated in tumor survival, yet its role in non-small cell lung cancer (NSCLC) chemoresistance remains unclear. We demonstrated that GSR is...
G. Panigrahi, Khushboo A Gandhi, Amisha Joshi et al.· Free Radical Biology & Medic...· 0 citations
A glutathione-responsive metal–organic framework nanoplatform for the co-delivery of curcumin and a GPX4-targeting antisense oligonucleotide (ASO) demonstrated robust anticancer effects in 3D multicellular tumor spheroids with a promoted oxidative imbalance.
Sen Li, Wen-Tao Wang, Yi-Zhang Chen et al.· Langmuir· 1 citation
In vivo, GPR39 knockdown significantly potentiated the antitumor activity of PD‐1 blockade, as evidenced by suppressed tumor progression accompanied by enhanced infiltration of CD8+ T cells, whereas ferroptosis inhibition abrogated these effects.
Cong Zhou, Xiao-Ling Fang, Jia-Ying Lin et al.· Canadian Journal of Gastroen...· 0 citations
The role of the HIF-1α-SREBP1-FASN/SCD1 signaling axis in ferroptosis regulation in glioma is systematically elucidated, providing important theoretical foundations and experimental support for developing HIF-1α-targeted ferroptosis therapies.
Zhong-Jun Shen, Yao Zhao, Ming-Bo Jia et al.· Journal of Lipid Research· 0 citations
These findings establish the UBR5-KDM5A-cAMP-PKA-SIRT3 axis as a central regulator of cisplatin resistance in TNBC and highlight KDM5A as a promising therapeutic target for combination treatment strategies.
Ming-Kai Gong, Fan Liang, Hu Wang et al.· Drug resistance updates· 0 citations